No Data
No Data
GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
GoodRx Holdings: Buy Rating Reaffirmed Amid Leadership Stability and Growth Prospects
Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Lowers Price Target to $6
GoodRx Holdings Analyst Ratings
Morgan Stanley Maintains GoodRx(GDRX.US) With Hold Rating, Cuts Target Price to $6
GoodRx Price Target Lowered to $6 From $7 at Morgan Stanley